Embecta(EMBC)

Focus: Embecta is a public diabetes care company focused on metabolic diseases, generating $1.1B in annual revenue with a specialized device and digital health portfolio.

Metabolic Diseases

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Embecta

AI assessmentNot Hiring

No open roles listed right now. Follow Embecta to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.1B

Pipeline & Clinical Trials

An AID System.

Type 2 Diabetes

N/A

Clinical Trials (1)

NCT06692153Embecta AID System in Adults With Type 2 Diabetes

N/A

Help build intelligence for Embecta

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Profitable mid-cap with $70M net income (FY2025) and stable $1.1B revenue base provides career security in a focused therapeutic area
Active pipeline development in automated insulin delivery systems signals innovation investment and R&D job growth potential
Public company status enables equity compensation and transparent growth trajectory for career planning

Watch Out For

Currently zero active job openings signals potential hiring freeze or organizational stability issues
Low R&D intensity (8%) and flat revenue growth (FY2024-2025) suggest limited pipeline expansion and career advancement pace
Modest clinical pipeline with only 2 trials and no early-phase programs indicates narrow therapeutic scope and specialization risk

Generated by Claude from Embecta's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Community-Derived Open-Source Automated Insulin Delivery Loop System

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT05951569Loop T2D Observational Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Metabolic Diseases

Publications: 14 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Metabolic Diseases

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$1.1B1%

R&D Spend

$85M(8%)27%

Net Income

$70M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Insulin Pen Needle Reuse in U.S. Adults with Diabetes: A Cross-Sectional Survey Study on Patterns, Motivations, and Educational Implications.

Diabetes therapy : research, treatment and education of diabetes and related disorders

2026

PMID:41735759

Artificial intelligence-driven clinical decision support systems to assist healthcare professionals and people with diabetes in Europe at the point of care: a Delphi-based consensus roadmap.

Diabetologia

2026

PMID:41247494

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo